Immunogenicity After Two Doses of Meningococcal Outer Membrane Vesicle Vaccine MenBVac

The main objective of the study is to estimate the proportion of children, born between the 01/01/2002 and the 06/23/200, living around Dieppe (cantons Dieppe est, Dieppe Ouest and Offranville), vaccinated by MenBVac, with a serum bactericidal activity against B:14,P1-7,16 clone related to a protection (>= 4), before and after the third MenBvac vaccination.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Vaccination

Age range

2 year–7 year

Sex eligibility

All sexes

Study type

Observational

Primary location

UH-rouen

Rouen, Seine Maritime, 76000, France

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

children born between 01/01/2000 and 06/23/2005, living in Dieppe-Est, Dieppe-Ouest and Offranville, vaccinated twice by MenBVac
parental authority(ies)assent

Exclusion criteria

no parental authority(ies)assent
no blood sample during the third vaccination
impossibility of third vaccination

Interested in participating?

Completed

Looking for future studies?

Notify Me

Sponsors and collaborators

Lead sponsor

University Hospital, Rouen

Other

Registry information

Official study title

EVALUATION DE LA REPONSE IMMUNITAIRE CONTRE LA SOUCHE DE NEISSERIA MENINGITIDIS B:14,P1.7,16

Important dates

Study start: 2007
Primary completion: 2008
Study completion: 2008
First posted: Mar 22, 2007
Registry last updated: Mar 27, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed